Biology of cerebral arteriovenous malformations with a focus on inflammation

Journal of Cerebral Blood Flow and Metabolism

Volumn 35, Issue 2, 2015, Pages 167-175

  Mouchtouris, Nikolaos ^a   Jabbour, Pascal M ^a   Starke, Robert M ^b   Hasan, David M ^c   Zanaty, Mario ^a,c   Theofanis, Thana ^a   Ding, Dale ^b   Tjoumakaris, Stavropoula I ^a   Dumont, Aaron S ^d   Ghobrial, George M ^a   Kung, David ^a   Rosenwasser, Robert H ^a   Chalouhi, Nohra ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

^c UNIVERSITY OF IOWA   (United States)

^d TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

angiogenesis; arteriovenous malformations; AVM; endothelial cell; inflammation; intracerebral hemorrhage

Indexed keywords

ENDOGLIN; HYPOXIA INDUCIBLE FACTOR 1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; NOTCH RECEPTOR; CELL ADHESION MOLECULE; GELATINASE B; MMP9 PROTEIN, HUMAN;

ANGIOGENESIS; B LYMPHOCYTE; BLOOD VESSEL PERMEABILITY; BRAIN ARTERIOVENOUS MALFORMATION; CYTOKINE RELEASE; DISEASE COURSE; EXTRACELLULAR MATRIX; GENETIC PREDISPOSITION; HUMAN; INFLAMMATION; MACROPHAGE; MICROGLIA; NEUTROPHIL; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; T LYMPHOCYTE; UPREGULATION; VASCULAR REMODELING; ANIMAL; BIOSYNTHESIS; DRUG EFFECTS; ENDOTHELIUM CELL; GENETICS; INTRACRANIAL ARTERIOVENOUS MALFORMATIONS; LEUKOCYTE; METABOLISM; PATHOLOGY;

ANIMALS; CELL ADHESION MOLECULES; ENDOTHELIAL CELLS; HUMANS; INFLAMMATION; INTRACRANIAL ARTERIOVENOUS MALFORMATIONS; LEUKOCYTES; MATRIX METALLOPROTEINASE 9; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, NOTCH; SIGNAL TRANSDUCTION; UP-REGULATION;

EID: 84922337343     PISSN: 0271678X     EISSN: 15597016     Source Type: Journal    
DOI: 10.1038/jcbfm.2014.179     Document Type: Review

References (101)

1. Berman MF, Sciacca RR, Pile-Spellman J, Stapf C, Connolly ES Jr., Mohr JP et al. The epidemiology of brain arteriovenous malformations. Neurosurgery 2000; 47: 389-396. discussion 97.
2. Gross BA, Du R. Natural history of cerebral arteriovenous malformations: a meta-analysis. J Neurosurg 2013; 118: 437-443.
3. Stapf C, Mast H, Sciacca RR, Berenstein A, Nelson PK, Gobin YP et al. The New York Islands AVM Study: design, study progress, and initial results. Stroke 2003; 34: e29-e33.
4. Hademenos GJ, Massoud TF. Risk of intracranial arteriovenous malformation rupture due to venous drainage impairment. A theoretical analysis. Stroke 1996; 27: 1072-1083.
5. Vinuela F, Nombela L, Roach MR, Fox AJ, Pelz DM. Stenotic and occlusive disease of the venous drainage system of deep brain AVM's. J Neurosurg 1985; 63: 180-184.
6. Mohr JP, Parides MK, Stapf C, Moquete E, Moy CS, Overbey JR et al. Medical management with or without interventional therapy for unruptured brain arteriovenous malformations (ARUBA): a multicentre, non-blinded, randomised trial. Lancet 2014; 383: 614-621.
7. Ondra SL, Troupp H, George ED, Schwab K. The natural history of symptomatic arteriovenous malformations of the brain: a 24-year follow-up assessment. J Neurosurg 1990; 73: 387-391.
8. Kim H, Sidney S, McCulloch CE, Poon KY, Singh V, Johnston SC et al. Racial/ethnic differences in longitudinal risk of intracranial hemorrhage in brain arteriovenous malformation patients. Stroke 2007; 38: 2430-2437.
9. Stapf C, Mohr JP, Choi JH, Hartmann A, Mast H. Invasive treatment of unruptured brain arteriovenous malformations is experimental therapy. Curr Opin Neurol 2006; 19: 63-68.
10. Novakovic RL, Lazzaro MA, Castonguay AC, Zaidat OO. The diagnosis and management of brain arteriovenous malformations. Neurol Clin 2013; 31: 749-763.
11. Fleetwood IG, Steinberg GK. Arteriovenous malformations. Lancet 2002; 359: 863-873.
12. Mohr JP, Parides MK, Stapf C, Moquete E, Moy CS, Overbey JR et al. Medical management with or without interventional therapy for unruptured brain arteriovenous malformations (ARUBA): a multicentre, non-blinded, randomised trial. Lancet 2014; 383: 614-621.
13. Hashimoto T, Lawton MT, Wen G, Yang GY, Chaly T Jr., Stewart CL et al. Gene microarray analysis of human brain arteriovenous malformations. Neurosurgery 2004; 54: 410-423. discussion 23-5.
14. Pawlikowska L, Tran MN, Achrol AS, McCulloch CE, Ha C, Lind DL et al. Polymorphisms in genes involved in inflammatory and angiogenic pathways and the risk of hemorrhagic presentation of brain arteriovenous malformations. Stroke 2004; 35: 2294-2300.
15. Rosenberg GA. Matrix metalloproteinases in neuroinflammation. Glia 2002; 39: 279-291.
16. Li X, Wang R, Wang X, Xue X, Ran D, Wang S. Relevance of IL-6 and MMP-9 to cerebral arteriovenous malformation and hemorrhage. Mol Med Rep 2013; 7: 1261-1266.
17. Achrol AS, Pawlikowska L, McCulloch CE, Poon KY, Ha C, Zaroff JG et al. Tumor necrosis factor-alpha-238G4A promoter polymorphism is associated with increased risk of new hemorrhage in the natural course of patients with brain arteriovenous malformations. Stroke 2006; 37: 231-234.
18. Sturiale CL, Puca A, Sebastiani P, Gatto I, Albanese A, Di Rocco C et al. Single nucleotide polymorphisms associated with sporadic brain arteriovenous malformations: where do we stand? Brain 2013; 136: 665-681.
19. Kim H, Hysi PG, Pawlikowska L, Poon A, Burchard EG, Zaroff JG et al. Common variants in interleukin-1-Beta gene are associated with intracranial hemorrhage and susceptibility to brain arteriovenous malformation. Cerebrovasc Dis 2009; 27: 176-182.
20. Fontanella M, Rubino E, Crobeddu E, Gallone S, Gentile S, Garbossa D et al. Brain arteriovenous malformations are associated with interleukin-1 cluster gene polymorphisms. Neurosurgery 2012; 70: 12-17.
21. Chen Y, Pawlikowska L, Yao JS, Shen F, Zhai W, Achrol AS et al. Interleukin-6 involvement in brain arteriovenous malformations. Ann Neurol 2006; 59: 72-80.
22. Storer KP, Tu J, Karunanayaka A, Morgan MK, Stoodley MA. Inflammatory molecule expression in cerebral arteriovenous malformations. J Clin Neurosci 2008; 15: 179-184.
23. Yao JS, Zhai W, Fan Y, Lawton MT, Barbaro NM, Young WL et al. Interleukin-6 upregulates expression of KDR and stimulates proliferation of human cerebrovascular smooth muscle cells. J Cereb Blood Flow Metab 2007; 27: 510-520.
24. Chen Y, Fan Y, Poon KY, Achrol AS, Lawton MT, Zhu Y et al. MMP-9 expression is associated with leukocytic but not endothelial markers in brain arteriovenous malformations. Front Biosci 2006; 11: 3121-3128.
25. Chen Y, Zhu W, Bollen AW, Lawton MT, Barbaro NM, Dowd CF et al. Evidence of inflammatory cell involvement in brain arteriovenous malformations. Neurosurgery 2008; 62: 1340-1349. discussion 9-50.
26. Hashimoto T, Wu Y, Lawton MT, Yang GY, Barbaro NM, Young WL. Coexpression of angiogenic factors in brain arteriovenous malformations. Neurosurgery 2005; 56: 1058-1065. discussion 65.
27. Rosenberg GA. Growth and bleeding in BAVM: another role for MMPs. Stroke 2003; 34: 925-931.
28. Lee CZ, Xu B, Hashimoto T, McCulloch CE, Yang GY, Young WL. Doxycycline suppresses cerebral matrix metalloproteinase-9 and angiogenesis induced by focal hyperstimulation of vascular endothelial growth factor in a mouse model. Stroke 2004; 35: 1715-1719.
29. Lee CZ, Xue Z, Zhu Y, Yang GY, Young WL. Matrix metalloproteinase-9 inhibition attenuates vascular endothelial growth factor-induced intracerebral hemorrhage. Stroke 2007; 38: 2563-2568.
30. Hashimoto T, Wen G, Lawton MT, Boudreau NJ, Bollen AW, Yang GY et al. Abnormal expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in brain arteriovenous malformations. Stroke 2003; 34: 925-931.
31. Hashimoto T, Matsumoto MM, Li JF, Lawton MT, Young WL. Suppression of MMP-9 by doxycycline in brain arteriovenous malformations. BMC Neurol 2005; 5: 1.
32. Lee CZ, Yao JS, Huang Y, Zhai W, Liu W, Guglielmo BJ et al. Dose-response effect of tetracyclines on cerebral matrix metalloproteinase-9 after vascular endothelial growth factor hyperstimulation. J Cereb Blood Flow Metab 2006; 26: 1157-1164.
33. Cheng SY, Nagane M, Huang HS, Cavenee WK. Intracerebral tumor-associated hemorrhage caused by overexpression of the vascular endothelial growth factor isoforms VEGF121 and VEGF165 but not VEGF189. Proc Natl Acad Sci USA 1997; 94: 12081-12087.
34. Asahi M, Wang X, Mori T, Sumii T, Jung JC, Moskowitz MA et al. Effects of matrix metalloproteinase-9 gene knock-out on the proteolysis of blood-brain barrier and white matter components after cerebral ischemia. J Neurosci 2001; 21: 7724-7732.
35. Hamann GF, Okada Y, del Zoppo GJ. Hemorrhagic transformation and microvascular integrity during focal cerebral ischemia/reperfusion. J Cereb Blood Flow Metab 1996; 16: 1373-1378.
36. Montaner J, Alvarez-Sabin J, Molina CA, Angles A, Abilleira S, Arenillas J et al. Matrix metalloproteinase expression is related to hemorrhagic transformation after cardioembolic stroke. Stroke 2001; 32: 2762-2767.
37. Wang X, Tsuji K, Lee SR, Ning M, Furie KL, Buchan AM et al. Mechanisms of hemorrhagic transformation after tissue plasminogen activator reperfusion therapy for ischemic stroke. Stroke 2004; 35(Suppl 11): 2726-2730.
38. Starke RM, Komotar RJ, Hwang BY, Hahn DK, Otten ML, Hickman ZL et al. Systemic expression of matrix metalloproteinase-9 in patients with cerebral arteriovenous malformations. Neurosurgery 2010; 66: 343-348. discussion 8.
39. Chen G, Zheng M, Shu H, Zhan S, Wang H, Zhou D et al. Macrophage migration inhibitory factor reduces apoptosis in cerebral arteriovenous malformations. Neurosci Lett 2012; 508: 84-88.
40. Noels H, Bernhagen J, Weber C. Macrophage migration inhibitory factor: a noncanonical chemokine important in atherosclerosis. Trends Cardiovasc Med 2009; 19: 76-86.
41. Schober A, Bernhagen J, Weber C. Chemokine-like functions of MIF in atherosclerosis. J Mol Med (Berl) 2008; 86: 761-770.
42. Lukes A, Mun-Bryce S, Lukes M, Rosenberg GA. Extracellular matrix degradation by metalloproteinases and central nervous system diseases. Mol Neurobiol 1999; 19: 267-284.
43. Uría J, López-Otín C. Matrix metalloproteinases as emerging targets for cancer therapy. Revista de Oncología 2000; 2: 282-293.
44. Nishida T, Faughnan ME, Krings T, Chakinala M, Gossage JR, Young WL et al. Brain arteriovenous malformations associated with hereditary hemorrhagic telangiectasia: gene-phenotype correlations. Am J Med Genet A 2012; 158A: 2829-2834.
45. Letteboer TG, Mager JJ, Snijder RJ, Koeleman BP, Lindhout D, Ploos van Amstel JK et al. Genotype-phenotype relationship in hereditary haemorrhagic telangiectasia. J Med Genet 2006; 43: 371-377.
46. Sabba C, Pasculli G, Lenato GM, Suppressa P, Lastella P, Memeo M et al. Hereditary hemorrhagic telangiectasia: clinical features in ENG and ALK1 mutation carriers. J Thromb Haemost 2007; 5: 1149-1157.
47. Bayrak-Toydemir P, McDonald J, Markewitz B, Lewin S, Miller F, Chou LS et al. Genotype-phenotype correlation in hereditary hemorrhagic telangiectasia: mutations and manifestations. Am J Med Genet A 2006; 140: 463-470.
48. Leblanc GG, Golanov E, Awad IA, Young WL. Biology of vascular malformations of the brain. Stroke 2009; 40: e694-e702.
49. van Laake LW, van den Driesche S, Post S, Feijen A, Jansen MA, Driessens MH et al. Endoglin has a crucial role in blood cell-mediated vascular repair. Circulation 2006; 114: 2288-2297.
50. Rossi E, Sanz-Rodriguez F, Eleno N, Duwell A, Blanco FJ, Langa C et al. Endothelial endoglin is involved in inflammation: role in leukocyte adhesion and transmigration. Blood 2013; 121: 403-415.
51. Matsubara S, Bourdeau A, terBrugge KG, Wallace C, Letarte M. Analysis of endoglin expression in normal brain tissue and in cerebral arteriovenous malformations. Stroke 2000; 31: 2653-2660.
52. Du R, Hashimoto T, Tihan T, Young WL, Perry V, Lawton MT. Growth and regression of arteriovenous malformations in a patient with hereditary hemorrhagic telangiectasia. Case report. J Neurosurg 2007; 106: 470-477.
53. Minakawa T, Tanaka R, Koike T, Takeuchi S, Sasaki O. Angiographic follow-up study of cerebral arteriovenous malformations with reference to their enlargement and regression. Neurosurgery 1989; 24: 68-74.
54. Black JE, Isaacs KR, Anderson BJ, Alcantara AA, Greenough WT. Learning causes synaptogenesis, whereas motor activity causes angiogenesis, in cerebellar cortex of adult rats. Proc Natl Acad Sci USA 1990; 87: 5568-5572.
55. Whitaker VR, Cui L, Miller S, Yu SP, Wei L. Whisker stimulation enhances angiogenesis in the barrel cortex following focal ischemia in mice. J Cereb Blood Flow Metab 2007; 27: 57-68.
56. Xu K, Lamanna JC. Chronic hypoxia and the cerebral circulation. J Appl Physiol (1985) 2006; 100: 725-730.
57. Li S, Chen BP, Azuma N, Hu YL, Wu SZ, Sumpio BE et al. Distinct roles for the small GTPases Cdc42 and Rho in endothelial responses to shear stress. J Clin Invest 1999; 103: 1141-1150.
58. Louissaint A Jr., Rao S, Leventhal C, Goldman SA. Coordinated interaction of neurogenesis and angiogenesis in the adult songbird brain. Neuron 2002; 34: 945-960.
59. Ardelt AA, McCullough LD, Korach KS, Wang MM, Munzenmaier DH, Hurn PD. Estradiol regulates angiopoietin-1 mRNA expression through estrogen receptoralpha in a rodent experimental stroke model. Stroke 2005; 36: 337-341.
60. Sato S, Kodama N, Sasaki T, Matsumoto M, Ishikawa T. Perinidal dilated capillary networks in cerebral arteriovenous malformations. Neurosurgery 2004; 54: 163-168. discussion 8-70.
61. Jabbour MN, Elder JB, Samuelson CG, Khashabi S, Hofman FM, Giannotta SL et al. Aberrant angiogenic characteristics of human brain arteriovenous malformation endothelial cells. Neurosurgery 2009; 64: 139-146. discussion 46-8.
62. Koizumi T, Shiraishi T, Hagihara N, Tabuchi K, Hayashi T, Kawano T. Expression of vascular endothelial growth factors and their receptors in and around intracranial arteriovenous malformations. Neurosurgery 2002; 50: 117-124. discussion 24-6.
63. Angelo LS, Kurzrock R. Vascular endothelial growth factor and its relationship to inflammatory mediators. Clin Cancer Res 2007; 13: 2825-2830.
64. Li A, Dubey S, Varney ML, Dave BJ, Singh RK. IL-8 directly enhanced endothelial cell survival, proliferation, and matrix metalloproteinases production and regulated angiogenesis. J Immunol 2003; 170: 3369-3376.
65. Dvorak HF. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med 1986; 315: 1650-1659.
66. Dvorak HF, Detmar M, Claffey KP, Nagy JA, van de Water L, Senger DR. Vascular permeability factor/vascular endothelial growth factor: an important mediator of angiogenesis in malignancy and inflammation. Int Arch Allergy Immunol 1995; 107: 233-235.
67. Dvorak HF, Harvey VS, Estrella P, Brown LF, McDonagh J, Dvorak AM. Fibrin containing gels induce angiogenesis. Implications for tumor stroma generation and wound healing. Lab Invest 1987; 57: 673-686.
68. Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS, Dvorak HF. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 1983; 219: 983-985.
69. Connolly DT, Olander JV, Heuvelman D, Nelson R, Monsell R, Siegel N et al. Human vascular permeability factor. Isolation from U937 cells. J Biol Chem 1989; 264: 20017-20024.
70. Roberts WG, Palade GE. Increased microvascular permeability and endothelial fenestration induced by vascular endothelial growth factor. J Cell Sci 1995; 108: 2369-2379.
71. Pepper MS, Ferrara N, Orci L, Montesano R. Potent synergism between vascular endothelial growth factor and basic fibroblast growth factor in the induction of angiogenesis in vitro. Biochem Biophys Res Commun 1992; 189: 824-831.
72. Lee CZ, Xue Z, Hao Q, Yang GY, Young WL. Nitric oxide in vascular endothelial growth factor-induced focal angiogenesis and matrix metalloproteinase-9 activity in the mouse brain. Stroke 2009; 40: 2879-2881.
73. Bhandari V, Choo-Wing R, Chapoval SP, Lee CG, Tang C, Kim YK et al. Essential role of nitric oxide in VEGF-induced, asthma-like angiogenic, inflammatory, mucus, and physiologic responses in the lung. Proc Natl Acad Sci USA 2006; 103: 11021-11026.
74. Ng I, Tan WL, Ng PY, Lim J. Hypoxia inducible factor-1alpha and expression of vascular endothelial growth factor and its receptors in cerebral arteriovenous malformations. J Clin Neurosci 2005; 12: 794-799.
75. Uranishi R, Baev NI, Kim JH, Awad IA. Vascular smooth muscle cell differentiation in human cerebral vascular malformations. Neurosurgery 2001; 49: 671-679. discussion 9-80.
76. Wautier MP, Boval B, Chappey O, Enjolras O, Wernert N, Merland JJ et al. Cultured endothelial cells from human arteriovenous malformations have defective growth regulation. Blood 1999; 94: 2020-2028.
77. Zhu Y, Lawton MT, Du R, Shwe Y, Chen Y, Shen F et al. Expression of hypoxiainducible factor-1 and vascular endothelial growth factor in response to venous hypertension. Neurosurgery 2006; 59: 687-696. discussion 96.
78. Sure U, Battenberg E, Dempfle A, Tirakotai W, Bien S, Bertalanffy H. Hypoxiainducible factor and vascular endothelial growth factor are expressed more frequently in embolized than in nonembolized cerebral arteriovenous malformations. Neurosurgery 2004; 55: 663-669. discussion 9-70.
79. Buell TJ, Ding D, Starke RM, Webster Crowley R, Liu KC. Embolization-induced angiogenesis in cerebral arteriovenous malformations. J Clin Neurosci 2014; http://dx.doi.org/10.1016/j.jocn.2014.04.010.
80. Sure U, Butz N, Schlegel J, Siegel AM, Wakat JP, Mennel HD et al. Endothelial proliferation, neoangiogenesis, and potential de novo generation of cerebrovascular malformations. J Neurosurg 2001; 94: 972-977.
81. Kim GH, Hahn DK, Kellner CP, Hickman ZL, Komotar RJ, Starke RM et al. Plasma levels of vascular endothelial growth factor after treatment for cerebral arteriovenous malformations. Stroke 2008; 39: 2274-2279.
82. Sandalcioglu IE, Wende D, Eggert A, Muller D, Roggenbuck U, Gasser T et al. Vascular endothelial growth factor plasma levels are significantly elevated in patients with cerebral arteriovenous malformations. Cerebrovasc Dis 2006; 21: 154-158.
83. Gunsilius E, Petzer A, Stockhammer G, Nussbaumer W, Schumacher P, Clausen J et al. Thrombocytes are the major source for soluble vascular endothelial growth factor in peripheral blood. Oncology 2000; 58: 169-174.
84. Salgado R, Benoy I, Bogers J, Weytjens R, Vermeulen P, Dirix L et al. Platelets and vascular endothelial growth factor (VEGF): a morphological and functional study. Angiogenesis 2001; 4: 37-43.
85. ZhuGe Q, Zhong M, Zheng W, Yang GY, Mao X, Xie L et al. Notch-1 signalling is activated in brain arteriovenous malformations in humans. Brain 2009; 132: 3231-3241.
86. Murphy PA, Lam MT, Wu X, Kim TN, Vartanian SM, Bollen AW et al. Endothelial Notch4 signaling induces hallmarks of brain arteriovenous malformations in mice. Proc Natl Acad Sci USA 2008; 105: 10901-10906.
87. Morrow D, Scheller A, Birney YA, Sweeney C, Guha S, Cummins PM et al. Notch-mediated CBF-1/RBP-J{kappa}-dependent regulation of human vascular smooth muscle cell phenotype in vitro. Am J Physiol Cell Physiol 2005; 289: C1188-C1196.
88. Carlson TR, Yan Y, Wu X, Lam MT, Tang GL, Beverly LJ et al. Endothelial expression of constitutively active Notch4 elicits reversible arteriovenous malformations in adult mice. Proc Natl Acad Sci USA 2005; 102: 9884-9889.
89. Murphy PA, Lu G, Shiah S, Bollen AW, Wang RA. Endothelial Notch signaling is upregulated in human brain arteriovenous malformations and a mouse model of the disease. Lab Invest 2009; 89: 971-982.
90. Jarriault S, Brou C, Logeat F, Schroeter EH, Kopan R, Israel A. Signalling downstream of activated mammalian Notch. Nature 1995; 377: 355-358.
91. Rosell A, Ortega-Aznar A, Alvarez-Sabín J, Fernández-Cadenas I, Ribó M, Molina CA et al. Increased brain expression of matrix metalloproteinase-9 after ischemic and hemorrhagic human stroke. Stroke 2006; 37: 1399-1406.
92. Baxter BT, Pearce WH, Waltke EA, Littooy FN, Hallett JW Jr., Kent KC et al. Prolonged administration of doxycycline in patients with small asymptomatic abdominal aortic aneurysms: report of a prospective (phase II) multicenter study. J Vasc Surg 2002; 36: 1-12.
93. Bendeck MP, Conte M, Zhang M, Nili N, Strauss BH, Farwell SM. Doxycycline modulates smooth muscle cell growth, migration, and matrix remodeling after arterial injury. Am J Pathol 2002; 160: 1089-1095.
94. Curci JA, Mao D, Bohner DG, Allen BT, Rubin BG, Reilly JM et al. Preoperative treatment with doxycycline reduces aortic wall expression and activation of matrix metalloproteinases in patients with abdominal aortic aneurysms. J Vasc Surg 2000; 31: 325-342.
95. Axisa B, Loftus IM, Naylor AR, Goodall S, Jones L, Bell PR et al. Prospective, randomized, double-blind trial investigating the effect of doxycycline on matrix metalloproteinase expression within atherosclerotic carotid plaques. Stroke 2002; 33: 2858-2864.
96. Walker EJ, Su H, Shen F, Degos V, Amend G, Jun K et al. Bevacizumab attenuates VEGF-induced angiogenesis and vascular malformations in the adult mouse brain. Stroke 2012; 43: 1925-1930.
97. Manning MW, Cassis LA, Daugherty A. Differential effects of doxycycline, a broad-spectrum matrix metalloproteinase inhibitor, on angiotensin II-induced atherosclerosis and abdominal aortic aneurysms. Arterioscler Thromb Vasc Biol 2003; 23: 483-488.
98. Murphy PA, Kim TN, Lu G, Bollen AW, Schaffer CB, Wang RA. Notch4 normalization reduces blood vessel size in arteriovenous malformations. Sci Transl Med 2012; 4: 117ra8.
99. Walker EJ, Su H, Shen F, Choi EJ, Oh SP, Chen G et al. Arteriovenous malformation in the adult mouse brain resembling the human disease. Ann Neurol 2011; 69: 954-962.
100. Hoang T, Huang S, Armstrong E, Eickhoff JC, Harari PM. Enhancement of radiation response with bevacizumab. J Exp Clin Cancer Res 2012; 31: 37.
101. Chalouhi N, Jabbour P, Magnotta V, Hasan D. Molecular imaging of cerebrovascular lesions. Transl Stroke Res 2014; 5: 260-268.